SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider George Cardoza Sells 1,592 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 1,592 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.10, for a total value of $12,895.20. Following the transaction, the chief financial officer directly owned 306,726 shares in the company, valued at approximately $2,484,480.60. This represents a 0.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Monday, September 21st, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.33, for a total value of $6,447.42.

SOPHiA GENETICS Trading Up 2.1%

SOPH opened at $7.30 on Friday. The firm has a 50 day simple moving average of $7.88 and a 200 day simple moving average of $6.15. SOPHiA GENETICS SA has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a market cap of $612.40 million, a price-to-earnings ratio of -6.35 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently bought and sold shares of the business. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at about $50,000. Royal Bank of Canada lifted its holdings in shares of SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the period. AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $119,000. Silverberg Bernstein Capital Management LLC boosted its position in shares of SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after acquiring an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in SOPHiA GENETICS in the second quarter valued at approximately $567,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SOPH. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.